Get notified of page updates

Policy Archive

EARLY Act Brings Young Breast Cancer to Forefront

Hereditary Cancer Awareness

The Breast Cancer Education and Awareness Requires Learning Young Act of 2009 (EARLY Act), HR 1740, was introduced by Representative Wasserman Schultz (D-FL), a breast cancer survivor who carries a BRCA2 mutation. FORCE participated in a coalition of groups providing guidance on the proposed legislation.

EARLY Act logoPassed as part of the Patient Protection and Affordable Care Act in March 2010, the EARLY Act authorized a nationwide awareness and support campaign for women age 45 and under, including high-risk women, breast cancer survivors, and their doctors. The law also includes broad-reaching public and healthcare professional education campaigns, prevention research, and additional support for young women diagnosed with breast cancer. Initially funded for five years, the EARLY Act Reauthorization of 2014 was passed on December 28, 2014. 

Since that time, the initiative has brought about a number of programs including the CDC's Bring Your Brave Campaign and Program Support for Survivor Organizations—including the FORCE XRAY Program, among other activities.

Take Action Now BECOME AN ADVOCATE 2023 Priorities Advocacy Archive Public Policy Initiatives

News Briefs

8/14/2023 - Joined stakeholders in a letter to the American College of Physicians expressing disappointment with the preventive colorectal cancer screening guidance it published, which conflicts with recommendations provided by the USPSTF, NCCRT, ACS, NCCN and other reputable organizations. 

7/21/2023 - Wrote House and Senate leadershipexpressing support for increased funding for the Agency for Healthcare Research and Quality (AHRQ) in its staffing and administrative support of the U.S. Preventive Services Task Force (USPSTF) as part of the FY24 appropriations bill.

6/7/2023 - Joined physicians and patient advocacy groups to support California AB 632, which will allow patients to receive prostate cancer screening without a deductible, copayment, or coinsurance for prostate cancer screening, including men over the age of 40 who are at high risk for prostate cancer.

More